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Abstract Heparin is shown to bind specifically to the carboxy-
terminal region of toxic type I phospholipase A2 from Naja
nigricollis (N-PLA2) by competition assay using synthetic
polypeptides and heparin affinity chromatography. The binding
strength is seen to depend on heparin chain length and the
presence of N-sulfate groups of heparin. It is observed that both
electrostatic and non-electrostatic interactions are involved in the
specific binding of heparin to the carboxy-terminus. When
heparin’s size is at least a decasaccharide, about two molecules of
N-PLA2 bind to one molecule of heparin, as evidenced by the
chemical estimate of protein to carbohydrate ratio in such N-
PLA2/heparin complexes. Based on such a stoichiometric
measurement and computer modeling of the N-PLA2/heparin
complex, it is suggested that the binding sites of the two N-PLA2
molecules on one heparin molecule lie on the opposite sides of the
heparin chain.
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1. Introduction
Phospholipases A2 (PLA2s), which catalyze the hydrolysis
of phospholipids at the sn-2 acyl chain and generate free fatty
acids and lysophospholipids, are involved in a variety of phys-
iological functions [1]. Mammalian secretory PLA2 including
human PLA2 (hIIa PLA2) are suggested to be associated with
the in£ammatory host-defense process [2]. On the other hand,
snake venom PLA2 causes tissue necrosis of the bitten victim
to exert its toxicity [3]. Glycosaminoglycans (GAGs) found on
the outer membrane of the cell, among which heparins have
the highest structural diversity and sulfate content, are pro-
posed to play important roles in regulating the enzymatic or
pharmacological action of these secretory class I and II PLA2s
[4]. It is suggested that the biological activities of these hep-
arin binding enzymes depend on whether proper and timely
presentation of these molecules could occur via their binding
to GAG molecules near the cell surface.
The heparin binding sites of di¡erent PLA2s from snake
venom have been assigned to be located at either the carboxy-
or amino-terminal region based on their sequence homology
and on whether heparin can inhibit their enzymatic activity
[5]. In most of these cases, the interactions of PLA2 with
heparin are electrostatic in nature, originating from the high
negative charge density of heparin. However, it is not known
whether non-electrostatic interactions between PLA2 and hep-
arin molecules are also involved as in the case of other hep-
arin binding proteins such as ¢broblast growth factor and
cobra cardiotoxins [6,7].
In the present study we investigate the nature of interaction
of N-PLA2, a basic PLA2 from Naja nigricollis, with heparin
and address the issue of the possible heparin chain length
dependence and the role of the presence of N-sulfate groups
in heparin on such an interaction. We combined the peptide
competition assay, enzymatic activity measurement, usage of
di¡erent chain length and de-N-sulfated heparin molecules,
computer modeling and other methods to obtain a clear
understanding of the above.
2. Materials and methods
2.1. Materials
Heparins with di¡erent molecular weights were purchased from
Sigma. Crude venom from Naja atra, Naja nigricollis and Naja mos-
sambica were also from Sigma. All PLA2s listed in Table 1 were
puri¢ed from crude venom by chromatography using SP-Sephadex
C-25, followed by reverse phase HPLC as described with modi¢cation
[8,9]. The assignments of these PLA2s were done by amino acid com-
position analysis, in combination with enzymatic activity measure-
ment [10].
Four polypeptides with amino acid sequences corresponding to
residues 51^57 (-YEKAGKM-), 63^69 (-LTLYKYK-), 111^117
(-NINFKKR-), and 111^119 (NINFKKRCQ-) of N-PLA2 molecules
and three other peptides with scramble, inverse and modi¢ed se-
quences of the intrinsic peptide 111^117, namely -NKNFQIRC-,
-QCRKKFNIN- and -NINFKKRCA-, respectively, were synthesized
by Genosys Biotech. Inc. using a segmented synthesis process [11].
2.2. Immobilized heparin binding assay
The e¡ective NaCl and polypeptide concentrations required to dis-
sociate the N-PLA2/heparin complex were determined using a hepa-
rin-Sepharose column (HiTrap, 1 ml, Pharmacia), ¢tted to a Bio-Rad
FPLC system [10] and a batch-type competition binding assay, respec-
tively. The latter was performed by incubating N-PLA2 (typically
40 WM) along with the desired concentrations of the synthetic poly-
peptides and heparin gel (10 Wl of swollen Sepharose gel with 1 Wg of
coupled heparin) pre-equilibrated with the binding bu¡er (10 mM
Tris-HCl, pH 8.0, 100 mM NaCl, and 0.02% NaN3). After 2 h of
incubation at room temperature, the reaction mixtures were centri-
fuged. The amount of eluted N-PLA2 was quanti¢ed by an enzymatic
method using the standard activity curve of N-PLA2 at various con-
centrations.
2.3. Enzyme depolymerization of heparin
Typically, 100 mg of porcine intestinal mucosal heparin was depo-
lymerized by 40 mIU Flavobacterium heparinase I (Sigma H-2519) in
a 1 ml reaction bu¡er as described previously [12]. Average molecular
weights and the corresponding carbohydrate chain lengths were esti-
mated from gradient polyacrylamide gel electrophoresis [13]. The mo-
lecular weight and compositions of depolymerized GAGs (dpGAGs),
ranging from a disaccharide to a decasaccharide, were characterized
by mass spectrometry and 2-D NMR spectroscopy (COSY and NO-
ESY), respectively as described [14,15]. Other than dpGAGs, heparin
of low molecular weight (LMW-heparin, MW V3000) with average
chain length greater than a decasaccharide is also used in these stud-
ies.
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2.4. Fluorescence experiments
8-Anilino-1-naphthalene sulfonate (ANS) was included in the N-
PLA2 containing solution to monitor the possible heparin-induced
£uorescence changes of the ANS bound to N-PLA2. The excitation
and emission wavelengths for ANS were set at 390 and 470 nm,
respectively, on a SLM 4800 £uorescence spectrometer. To determine
the dissociation constant (Kd), computer simulation was performed
based on the equation: Kd = ([H]t3[PnH])([P]t3n[PnH])/[PnH], where
[P], [H] and [PnH] represent the concentrations of PLA2, heparin and
PLA2/heparin complex, respectively [5].
2.5. Molecular modeling
Molecular modeling was conducted using Insight II on a SGI O2
workstation (Silicon Graphics, Inc.). A computer model of N-PLA2
was constructed using the known crystal structure of PLA2 from Naja
atra, A-PLA2 (V80% homology to N-PLA2 based on the amino acid
sequence) [16] as starting geometry. Simulations of heparin’s binding
to N-PLA2 were performed through seven docking experiments,
where heparin was initially docked near the charge cluster III (Table
1), i.e., around Lys-114, Lys-115 and Arg-116 in accordance with
previous binding results. Molecular dynamics simulation with a time
step of 1 fs was used to obtain the model of the N-PLA2/heparin
complex after 10^40 ps. The non-bonded cuto¡ value was set at
15 Aî . Energy minimization of the complex was ¢nally performed to
remove improper atom contacts and forces.
3. Results and discussion
3.1. Heparin a⁄nity chromatography
By determining the NaCl concentration required to elute
di¡erent cobra PLA2s (listed in Table 1) from the heparin
a⁄nity column and correlating it with the amino acid sequen-
ces of homologous PLA2 from Taiwan and African cobras,
we could identify three potential amino acid positions in-
volved in heparin binding (marked by asterisks in Table 1).
They are near Lys-53, Lys-70, and Lys-118 (Table 1) and are
classi¢ed here as positively charged clusters I, II, and III of
cobra basic PLA2, respectively. It was observed that addition
of LMW-heparin did not alter the enzymatic activity of
N-PLA2 toward DMPC/Triton X-100 mixed micelles (Km
for N-PLA2 is 0.17 þ 0.03 and 0.19 þ 0.06 mM without and
with 0.3 WM LMW-heparin, respectively) as well as its Ca2-
dependent activity. Thus it appears that heparin binds to
N-PLA2 in locations far away from the enzymatic catalytic
regions.
Table 1
Correlation of amino acid sequences of PLA2s from Taiwan and African cobras and NaCl concentration required to dissociate the heparin-
PLA2 complex
A-, N-, and M-PLA2 denote PLA2s from Naja atra, Naja nigricollis and Naja mossambica, respectively, where M1, M2, and M3-PLA2 are sub-
divisions of the same venom from Naja mossambica.
*Potential heparin binding site.
@Salt concentration required to elute PLA2 from the heparin a⁄nity column.
#Flow-through (F.T.) of the heparin a⁄nity column during the initial loading in 10 mM Tris. The deviation was estimated from the possible
dead volume and the fraction volume during sample collection.
Fig. 1. Competition of binding between synthetic polypeptides and
N-PLA2 toward immobilized heparin. Polypeptides used here corre-
spond to the indicated amino acid sequences derived from N-PLA2.
Approximately 1 Wg of immobilized heparin was mixed with 40 WM
of N-PLA2 and increasing amounts of polypeptides were added to a
¢nal volume of 120 Wl of binding bu¡er. The unbound N-PLA2
that was released free in the supernatant was quanti¢ed by an enzy-
matic method using the standard activity curve of N-PLA2 at vari-
ous concentrations. (b) Peptide 110^118; (a) peptide 110^116; (R)
peptide 110^118 with Ala substituted for Gln; (O) inverse peptide
of 110^118; (F) scramble peptide of 110^118; (8) peptide 51^57;
and (7) peptide 63^69. Values are the mean of triplicate as-
says þ S.D. If not shown, S.D. is smaller than the symbol size.
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3.2. Polypeptide competition experiments
Fig. 1 shows the concentration of whole N-PLA2 that is
displaced into bu¡er due to the more favored binding of com-
peting polypeptide to heparin. The peptide with its sequence
corresponding to region III, i.e. 111^117 near the carboxy-
terminus, exhibits signi¢cant competition with N-PLA2. This
interaction is speci¢c since hepta peptide 111^117 (open circle)
competes quite favorably with N-PLA2 whereas the other two
hepta peptides 51^57 (region I) and 63^69 (region II) (closed
and open diamonds) shows little ability to do so. Such specif-
icity does not arise merely because of the presence of three
positively charged amino acid residues in the peptide 111^117,
compared to only two positively charged residues in 51^57
and 63^69. This is because the inclusion of two additional
non-charged residues, i.e. Cys-Gln, at the carboxy-terminus
increases the binding by almost one order of magnitude (com-
pare closed and open circles). Secondly, substitution of Gln by
Ala (closed triangle) reduces its binding a⁄nity by a similar
amount, suggesting that the enhanced activity is not due to
the potential oxidation of the introduced free Cys residues.
Thirdly, the control peptides with reversed (open triangle)
and scrambled (closed square) sequences derived from the
intrinsic sequence (111^117) near the carboxy-terminus exhibit
weaker binding than the intrinsic one itself. This is conclusive
for the fact that heparin can indeed bind to the carboxy-ter-
minus of N-PLA2 via both electrostatic interaction and non-
electrostatic interaction (probably by hydrogen bond forma-
tion) and this binding is quite speci¢c to the sequence of the
amino acids near the carboxy-terminus.
3.3. Heparin chain length and N-sulfation-dependent binding
Having identi¢ed the possible binding site of N-PLA2 to
heparin to be near the carboxy-terminus we looked for possi-
ble dependence of the binding on heparin’s chain length. Fig.
2A shows a steady increase in the ANS £uorescence intensity
with increasing dpGAG concentrations for di¡erent chain
lengths, from a disaccharide to an octasaccharide. The Kd
values for di¡erent dpGAG chain lengths indicate that
dpGAG’s binding strength can increase by about 50-fold
when chain length varies from a tetrasaccharide to an octa-
saccharide. However, a heparin molecule with chain length of
a tetrasaccharide can itself cover the binding site near the C-
terminus of N-PLA2, implying that other regions of heparin
should also participate in the binding.
Apart from heparin chain length, the presence of sulfate
groups is also found to be important in a binding event of
heparin with N-PLA2. As seen in Fig. 2B, binding strength of
de-N-sulfated heparin to N-PLA2 is markedly reduced as
compared with the same for regular LMW-heparin. Thus
the N-sulfate group of heparin must also be involved in an
important manner in the speci¢c interaction of heparin with
N-PLA2.
3.4. Oligomer formation and stoichiometry of the N-PLA2/
LMW-heparin complex
Measurement of turbidity changes for N-PLA2/heparin
mixtures at di¡erent heparin concentrations (data not shown)
showed signi¢cant oligomerization of N-PLA2/heparin com-
plexes for heparin chain lengths longer than an octasaccha-
ride. The stoichiometric ratios of protein to carbohydrate in
such complexes were assayed directly [17]. The ratios are seen
to be 2.38, 1.93 and 1.85 for N-PLA2/LMW-heparin ratios of
10/8, 10/25 and 10/200, respectively. Thus heparin possibly has
two N-PLA2 binding sites and, on average, there are two
N-PLA2 molecules per heparin in the observed N-PLA2/
LMW-heparin complexes.
3.5. Molecular docking of heparin with N-PLA2
Shown in Fig. 3 are the results of docking experiments on
the computer between heparin and N-PLA2. The top panel of
Fig. 3A provides the 3-D structure of the decasaccharide hep-
arin molecule and the middle panel shows the stereo view of
this heparin bound to N-PLA2. Most of the observed inter-
actions occur between the positively charged cluster near the
carboxy-terminus and the anionic sulfate residue of IdoA-8
and GlcN-9 (Fig. 3A). Speci¢cally, the 2-N-SO33 and 6-O-
SO33 of GlcN-9 can be seen to interact with Lys-114, 115
and Arg-116 of N-PLA2 molecules, respectively (bottom panel
Fig. 2. E¡ect of using dpGAGs with di¡erent chain lengths on the
binding with N-PLA2. dpGAG#n denotes a heparin chain of n sac-
charide units. A: Relative changes in ANS £uorescence intensity at
the indicated chain lengths: (7) dpGAG#2; (b) dpGAG#4; (a)
dpGAG#6 and (R) dpGAG#8. Fluorescence changes (vI) of the
enzyme-bound ANS (60 WM) for 2 WM N-PLA2 in the presence of
increasing quantities of dpGAGs were calculated from the average
£uorescence intensities at 470 nm. Data were then analyzed by non-
linear regression with a constraint of only one binding site. The Kd
of N-PLA2/dpGAG complexes for dpGAG with chain length of #2,
#4, #6, and #8 were found to be s 100, 37 þ 2, 8.1 þ 0.7, and
0.7 þ 0.1, respectively. B: The N-sulfate group of heparin is involved
in the binding as evidenced by the dependence of relative ANS £uo-
rescence changes as a function of LMW-heparin (b) and de-N-sul-
fated heparin (a) concentration.
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of Fig. 3A). Nevertheless, consistent with our experimental
data, several non-electrostatic hydrogen bond interactions
can be found between the 3-OH of IdoA-8 and the last two
amino acid residues in the carboxy-terminus. Lys-33, which is
located far away from the identi¢ed positively charged clusters
based on primary amino acid sequence, interacts strongly with
2-O-SO33 of IdoA-8. The model depicted here consists of the
important feature that a quasi-symmetric N-PLA2 binding site
is also available on the heparin molecule on the opposite side
of the original binding site if its chain length is equal to or
longer than a decasaccharide. This can be inferred from the
optimally bound con¢guration of the dodecasaccharide chain
with the N-PLA2 molecules shown in Fig. 3B. The most prob-
able form of the heparin/N-PLA2 complex implied from this
model is two N-PLA2 bound to one heparin chain and this is
consistent with the direct measurement of stoichiometry be-
tween heparin and N-PLA2 in the observed complexes. The
aggregation of these complexes is a possibility, when increased
areas of hydrophobic regions of N-PLA2 are exposed upon
heparin’s binding and this is perhaps what is indicated by the
enhanced ANS £uorescence intensity following the initial
binding of heparin with N-PLA2 (Fig. 2A).
Thus, the data presented show that N-PLA2 binds to hep-
arin via its C-terminal region and a possible dimer complex is
formed at a protein to carbohydrate ratio of 2:1. Although
the possibility of electrostatic interactions in regions other
than the C-terminus is seen (between positively charged Lys-
83, Lys-56, and negatively charged 6-O-SO33 of GlcN-1 and 6-
CO32 of IdoA-2; Fig. 3B), the binding near the C-terminus
depends on both electrostatic and non-electrostatic interac-
tions. The binding seems to be speci¢c to the amino acid
sequence and the strength is dependent on the length of the
heparin chain as well as the presence of N-sulfate groups on
heparin. The formation of dimer complexes assumes signi¢-
cance when we note that the crystal structures of many snake
venom PLA2s exhibit either a dimeric or a trimeric form with
unknown biological activity [18].
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